Citation
Comi, Giancarlo, et al. "Efficacy of Alemtuzumab in Relapsing-remitting MS Patients Who Received Additional Courses After the Initial Two Courses: Pooled Analysis of the CARE-MS, Extension, and TOPAZ Studies." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 26, no. 14, 2020, pp. 1866-1876.
Comi G, Alroughani R, Boster AL, et al. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult Scler. 2020;26(14):1866-1876.
Comi, G., Alroughani, R., Boster, A. L., Bass, A. D., Berkovich, R., Fernández, Ó., Kim, H. J., Limmroth, V., Lycke, J., Macdonell, R. A., Sharrack, B., Singer, B. A., Vermersch, P., Wiendl, H., Ziemssen, T., Jacobs, A., Daizadeh, N., Rodriguez, C. E., & Traboulsee, A. (2020). Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis (Houndmills, Basingstoke, England), 26(14), 1866-1876. https://doi.org/10.1177/1352458519888610
Comi G, et al. Efficacy of Alemtuzumab in Relapsing-remitting MS Patients Who Received Additional Courses After the Initial Two Courses: Pooled Analysis of the CARE-MS, Extension, and TOPAZ Studies. Mult Scler. 2020;26(14):1866-1876. PubMed PMID: 31762387.
TY - JOUR
T1 - Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
AU - Comi,Giancarlo,
AU - Alroughani,Raed,
AU - Boster,Aaron L,
AU - Bass,Ann D,
AU - Berkovich,Regina,
AU - Fernández,Óscar,
AU - Kim,Ho Jin,
AU - Limmroth,Volker,
AU - Lycke,Jan,
AU - Macdonell,Richard Al,
AU - Sharrack,Basil,
AU - Singer,Barry A,
AU - Vermersch,Patrick,
AU - Wiendl,Heinz,
AU - Ziemssen,Tjalf,
AU - Jacobs,Alan,
AU - Daizadeh,Nadia,
AU - Rodriguez,Claudio E,
AU - Traboulsee,Anthony,
AU - ,,
Y1 - 2019/11/25/
PY - 2019/11/26/pubmed
PY - 2019/11/26/medline
PY - 2019/11/26/entrez
KW - Alemtuzumab
KW - efficacy
KW - multiple sclerosis
KW - relapse
KW - retreatment
KW - safety
SP - 1866
EP - 1876
JF - Multiple sclerosis (Houndmills, Basingstoke, England)
JO - Mult Scler
VL - 26
IS - 14
N2 - BACKGROUND: Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. OBJECTIVE: To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. METHODS: Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); <12-month follow-up after last alemtuzumab course. RESULTS: In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. CONCLUSION: Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
SN - 1477-0970
UR - https://www.unboundmedicine.com/medline/citation/31762387/Efficacy_of_alemtuzumab_in_relapsing_remitting_MS_patients_who_received_additional_courses_after_the_initial_two_courses:_Pooled_analysis_of_the_CARE_MS_extension_and_TOPAZ_studies_
L2 - https://journals.sagepub.com/doi/10.1177/1352458519888610?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
DB - PRIME
DP - Unbound Medicine
ER -